


Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

1. (Currently Amended) \pm A compound of formula I



in a crystal form B that has a melting point, by Differential Scanning Calorimetry, of about 270°C with simultaneous decomposition, at a heating rate of 20°C/min and the following characteristic diffraction lines (2θ in angular degrees $\pm 0.2^\circ$) in the X-ray diffraction pattern thereof: 7.2°, 9.3°, 12.0°, 12.8°, 13.1°, 14.5°, 17.4°, 20.4°, 23.2° and 25.8°.


2. (Original) A pharmaceutical composition comprising, as active ingredient, an effective amount of the compound of formula I in crystal form B as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
3. (Original) A composition according to claim 2, which is in inhalable form.

4-7. (Cancelled)

8. (Previously Presented) A pharmaceutical composition comprising a compound of formula I as defined in claim 1 in combination with another drug substance which is an anti-inflammatory or a bronchodilator.

9. (Previously Presented) A composition according to claim 8 wherein the another drug substance is a beta-2 adrenoceptor agonist.

10. (Currently Amended) A composition according to claim 9 wherein the beta-2 adrenoceptor agonist is selected from the group consisting of salbutamol, terbutaline, salmeterol, formoterol and the compound of formula



in free or pharmaceutically acceptable salt or solvate form.

11. (Previously Presented) A method of treating an inflammatory or obstructive airways disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound according to claim 1 in crystal form B as defined in claim 1.

12. (Previously Presented) A method of treating asthma or chronic obstructive pulmonary disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound according to claim 1 in crystal form B as defined in claim 1.

13. (Previously Presented) A method of treating atopic dermatitis in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound according to claim 1 in crystal form B as defined in claim 1.

14. (Previously Presented) A method of preparing a compound of formula I in crystal form B as defined in claim 1 which comprises crystallising the compound of formula I as defined in claim 1 from a solution thereof in ethanol, methanol or methylene chloride.